Advertisement

Adenosine Injection

[26 August 2015]

Products Affected - Description

Use in Paroxysmal Supraventricular Tachycardia
Adenosine intravenous injection, Akorn
3 mg/mL, 2 mL vial, 10 count (NDC 17478-0542-02)


Adenosine intravenous injection, Sagent
3 mg/mL, 2 mL vial, 10 count (NDC 25021-0301-02)
3 mg/mL, 4 mL vial, 10 count (NDC 25021-0301-04)

Adenosine intravenous injection, West-Ward
3 mg/mL, 2 mL vial, 10 count (NDC 00641-6113-10)

Diagnostic Adjunct
Adenosine intravenous injection, Sagent
3 mg/mL, 30 mL vial, 1 count (NDC 25021-0307-30)

Reason for the Shortage

  • Astellas discontinued Adenoscan in April 2015. Adenoscan is used for diagnostic purposes as an adjunct to thallium-201 myocardial perfusion scintigraphy. Adenocard and generic adenosine products are labeled for use in paroxysmal supraventricular tachycardia.
  • Sagent has adenosine vials on shortage due to increased demand..
  • West-Ward has adenosine injection on shortage due to manufacturing delays.

Available Products

Use in Paroxysmal Supraventricular Tachycardia
Adenosine intravenous injection, Akorn
3 mg/mL, 2 mL vial, 25 count (NDC 17478-0542-25)
 
Adenosine intravenous injection, Fresenius Kabi
3 mg/mL, 2 mL vial, 10 count (NDC 63323-0651-02)
3 mg/mL, 4 mL vial, 10 count (NDC 63323-0651-04)
 
Adenosine intravenous injection, Sagent
3 mg/mL, 2 mL prefilled syringe, 10 count (NDC 25021-0301-67)
3 mg/mL, 4 mL prefilled syringe, 10 count (NDC 25021-0301-68)
 
Adenocard intravenous injection, Astellas
3 mg/mL, 2 mL prefilled syringe, 10 count (NDC 00469-8234-12)
3 mg/mL, 4 mL prefilled syringe, 10 count (NDC 00469-8234-14)

Diagnostic Adjunct
Adenosine intravenous injection, Akorn
3 mg/mL, 30 mL vial, 1 count (NDC 17478-0544-30)
3 mg/mL, 20 mL vial, 1 count (NDC 17478-0544-20)

Adenosine intravenous injection, Sagent
3 mg/mL, 20 mL vial, 1 count (NDC 25021-0307-20)

Adenosine intravenous injection, Teva
3 mg/mL, 20 mL vial, 1 count (NDC 00703-8776-01)
3 mg/mL, 30 mL vial, 1 count (NDC 00703-8777-01)

Estimated Resupply Dates

  • Akorn has adenosine 3 mg/mL 2 mL vials in 10 count size available in limited supply.
  • Sagent has adenosine 3 mg/mL 30 mL vials on back order and the company estimates a release date in October 2015. Sagent has adenosine 3 mg/mL 2 and 4 mL vials on back order and the company estimates a release date in October 2015.
  • West-Ward has adenosine 3 mg/mL 2 mL vials on back order and the company cannot estimate a release date.

Related Shortages

Updated

August 26 and 12, July 9, June 25, May 20 and 27, April 16 and 27, March 4, 5, 12, 20, and 27, February 20, January 9, 26, and 29, 2015; December 15, November 17, September 8 and 23, August 4, July 3 and 18, May 7, 13, 15, and 22, 2014; April 1, 24, and 25, March 4, 14, 17, and 28, February 12 and 21, January 14, 2014; December 11, October 18, September 16, August 15 and 29, July 18, June 18, May 13 and 15, April 11, March 1 and 13, February 13, and January 25, 2013; December 21 and 28, November 19, 2012, University of Utah, Drug Information Service. Copyright 2015, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
Advertisement